Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still’s disease

We report on a 64-year-old woman with multirefractory flare of adult-onset Still’s disease successfully treated with six-month course of add-on anti-interleukin 6 receptor antibody, tocilizumab. Before administration of tocilizumab, the combination therapy with 80 mg/day of prednisolone and cyclospo...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2013-03, Vol.32 (Suppl 1), p.103-106
Main Authors: Naniwa, Taio, Ito, Rei, Watanabe, Maiko, Hayami, Yoshihito, Maeda, Shinji, Sasaki, Kaneshige, Iwagaitsu, Shiho
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Case Report
Case reports
Cyclosporine - therapeutic use
Cyclosporins
Dose-Response Relationship, Drug
Drug Resistance, Multiple - drug effects
Drug Therapy, Combination
Female
Humans
Immunoglobulins, Intravenous - therapeutic use
Immunologic Factors - therapeutic use
Interleukin 6
Intravenous administration
Medicine
Medicine & Public Health
Methylprednisolone
Methylprednisolone - therapeutic use
Middle Aged
Prednisolone
Prednisolone - therapeutic use
Pulse Therapy, Drug
Recurrence
Remission
Remission Induction
Rheumatology
Still's Disease, Adult-Onset - drug therapy
Tacrolimus
Tacrolimus - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report on a 64-year-old woman with multirefractory flare of adult-onset Still’s disease successfully treated with six-month course of add-on anti-interleukin 6 receptor antibody, tocilizumab. Before administration of tocilizumab, the combination therapy with 80 mg/day of prednisolone and cyclosporine or tacrolimus for five weeks, two courses of pulse methylprednisolone, and high-dose intravenous immunoglobulin could not control the disease. Add-on tocilizumab dramatically improved her disease state and enabled tapering of corticosteroid and tacrolimus. Furthermore remission has been maintained on low-dose corticosteroid and tacrolimus after withdrawal of tocilizumab. This case report suggests that short-term add-on tocilizumab might be a useful therapeutic option for patients with multirefractory flare of polycyclic systemic adult-onset Still’s disease.
ISSN:0770-3198
1434-9949
DOI:10.1007/s10067-010-1562-8